Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...
In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...
Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash ...
A clinical trial testing an experimental vaccine for the Epstein-Barr virus (EBV) in people with MS is now recruiting ...
In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.
Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...
Moderna is currently in the middle of an aggressive cost-cutting campaign. In September last year, the company announced that ...
Jay Bhattacharya's new "plan" is really an admission that if there's a new pandemic, he’s not competent enough to do any of ...
With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...
With much of Moderna’s rise in this decade tied to its COVID-19 vaccine, the company has struggled in recent years to match ...
At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set the stage for additional growth ...
Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback